

CAMSON BIO TECHNOLOGIES LIMITED
STATEMENT OF UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPT 2014

PART I

Sl. No.	Particulars	Rupees in Lakhs					
		Quarter Ended			Half Year Ended		Previous Year Ended
		30th Sept 2014 (Unaudited)	30th June 2014 (Unaudited)	30th Sept 2013 (Unaudited)	30th Sept 2014 (Unaudited)	30th Sept 2013 (Unaudited)	
1	Income from Operations						
	(a) Net sales / income from Operations (Net of Excise duty)	4,156.96	3,572.99	3,191.99	7,729.95	6,263.44	14,562.78
	(b) Other Operating Income	-	-	-	-	-	-
	Total Income from Operations (net)	4,156.96	3,572.99	3,191.99	7,729.95	6,263.44	14,562.78
2	Expenses						
	(a) Cost of Materials consumed	1,730.02	688.84	490.24	2,418.86	781.45	2,131.52
	(b) Purchase of stock-in-trade	1,933.07	6.49	1,195.00	1,939.56	1,895.09	4,866.83
	(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	(2,445.84)	897.40	(379.88)	(1,548.44)	73.29	(291.73)
	(d) Employee benefits expense	325.21	285.95	203.95	611.16	369.70	856.76
	(e) Depreciation and amortisation expense	335.92	334.10	125.57	670.02	249.02	511.30
	(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)						
	Total Expenses	138.73	190.50	85.27	329.23	137.04	410.59
	ii Selling and Promotion Expenses	810.23	158.80	750.41	969.03	1,066.31	1,931.16
	iii Other Expenses	1,206.18	620.69	578.99	1,826.87	869.05	2,189.45
	Total Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	4,033.52	3,182.77	3,049.55	7,216.29	5,440.95	12,605.88
3	Other income	13.10	1.39	31.19	14.49	43.90	53.28
4	Finance Cost	136.54	391.61	173.63	528.15	866.39	2,010.18
5	Exceptional Items	67.17	107.31	85.29	174.48	175.21	386.86
6	Profit / (Loss) from ordinary activities before finance costs but before exceptional items (5 + 6)	69.37	284.30	88.34	353.67	356.30	356.30
7	Profit / (Loss) from ordinary activities before tax (7 + 8)	69.37	284.30	88.34	353.67	334.88	1,267.02
8	Tax Expense	43.60	(117.10)	56.00	(73.50)	66.00	(60.10)
9	Net Profit / (Loss) form Ordinary Activities after tax (9 + 10)	25.77	401.40	32.34	427.17	268.88	1,327.12
10	Extraordinary Items (net of tax expenses)						
11	Net Profit / (Loss) for the period (11 + 12)	25.77	401.40	32.34	427.17	268.88	1,327.12
12	Share of Profit / (loss of associates)						
13	Minority Interest						
14	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15)	25.77	401.40	32.34	427.17	268.88	1,327.12
15	Paid up Equity Share Capital (Face value of the Share is Rs. 10/-)	2,999.98	2,832.55	2,522.55	2,999.98	2,522.55	2,522.55
16	Reserves excluding Revaluation Reserve as per Balance Sheet of the Previous Accounting Year						17,863.38
17	Earning per share (before extraordinary items) (of Rs.10 /- each) (not annualised): Rs						
18	(a) Basic	0.09	1.57	0.13	1.42	1.10	5.65
19	(b) diluted	0.09	1.27	0.12	1.42	0.97	4.72
19.i	Earning per share (after extraordinary items) (of Rs.10 /- each) (not annualised): Rs						
19.ii	(a) Basic	0.09	1.57	0.13	1.42	1.10	5.65
19.iii	(b) diluted	0.09	1.27	0.12	1.42	0.97	4.72



[Handwritten Signature]

CAMISON BIO TECHNOLOGIES LIMITED
PART II SELECT INFORMATION FOR THE QUARTER AND HALF YEAR ENDED AS ON 30TH SEPT 2014

Sl. No.	Particulars	Standalone						Previous Year Ended 31st Mar 2014 (Audited)
		Quarter Ended		Half Year Ended		30th Sept 2013 (Unaudited)	30th Sept 2013 (Unaudited)	
		30th Sept 2014 (Unaudited)	30th June 2014 (Unaudited)	30th Sept 2014 (Unaudited)	30th Sept 2014 (Unaudited)			
A	PARTICULARS OF SHAREHOLDING							
1	Public Shareholding	2,26,61,240	2,09,86,913	1,74,86,913	1,74,86,913	1,74,86,913	1,74,86,913	1,85,86,913
	- Number of Shares *	75.54%	74.09%	76.33%	76.33%	75.54%	78.33%	73.68%
2	Promoters and Promoter group shareholding							
a)	Pledged/Encumbered - Number of Shares	0%	0%	0%	0%	0%	0%	0%
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0%	0%	0%	0%	0%	0%	0%
	Percentage of shares (as a % of the total share capital of the company)	0%	0%	0%	0%	0%	0%	0%
b)	Non-encumbered							
	Number of shares	73,38,600	73,38,600	48,38,600	48,38,600	73,38,600	48,38,600	66,38,600
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%	100%
	Percentage of Shares (as a % of the total share Capital of the Company)	24.46%	25.91%	21.67%	21.67%	24.46%	21.67%	26.32%

B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	Nil
	Disposed of during the quarter	Nil
	Remaining unresolved at the end of the quarter	Nil



CAMSON BIO TECHNOLOGIES LIMITED
REPORT OF SEGMENT-WISE CONSOLIDATED REVENUE, RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE 41 OF THE LISTING AGREEMENT FOR QUARTER AND HALF YEAR ENDED AS ON 30TH SEPT 2014

Rupees in Lakhs

Sl. No.	Particulars	Standalone					Previous Year Ended 31st Mar 2014 (Audited)
		Quarter Ended		Half Year Ended		30th Sept 2013 (Unaudited)	
		30th Sept 2014 (Unaudited)	30th June 2014 (Unaudited)	30th Sept 2014 (Unaudited)	30th Sept 2013 (Unaudited)		
1	Segment Revenue						
	a) Seeds	1,948.56	2,552.26	4,500.82	4,117.22	10,260.12	
	b) Agribiotech Products	2,208.40	1,020.73	3,229.13	2,146.22	4,302.66	
	c) Others						
	Total	4,156.96	3,572.99	7,729.95	6,263.44	14,562.78	
	Less: Intersegment Revenue						
	Net Sales/ Income from Operation	4,156.96	3,572.99	7,729.95	6,263.44	14,562.78	
2	Segment Results						
	Profit (+) / Loss (-) before tax and interest from each segment						
	a) Seeds	22.10	482.25	504.35	432.16	2,058.95	
	b) Agribiotech Products	365.01	96.00	461.01	303.61	443.53	
	Total	387.11	578.25	965.36	735.77	2,502.48	
	Less: (i) Other Net unallocated Income / expenses	250.56	186.64	437.20	225.68	848.60	
	(ii) Finance Cost	67.17	107.31	174.48	175.21	386.86	
	Total Profit before Tax	69.38	284.30	353.68	334.88	1,267.02	
3	Capital Employed						
	(Segment Assets-Segment Liabilities)						
	a) Seeds	13,041.98	13,023.42	13,041.98	12,350.67	12,908.54	
	b) Agri Biotech products	8,863.12	9,297.81	8,863.12	7,069.76	8,633.73	
	c) Others	4,184.69	1,396.28	4,184.69	1,258.13	1,154.69	
	TOTAL	26,089.79	23,717.51	26,089.79	20,678.56	22,696.96	



CAMSON BIO TECHNOLOGIES LIMITED

STATEMENT OF ASSETS AND LIABILITIES UNDER CLAUSE 41(v) OF THE LISTING AGREEMENT

Sl. No	PARTICULARS	Standalone	
		As at 30-Sept-14 (Unaudited)	As at 31-Mar-14 (Audited)
A	EQUITY AND LIABILITIES		
1	Shareholders' Funds		
	(a) Share Capital	2,999.98	2,522.55
	(b) Reserves and Surplus	23,089.68	17,863.38
	(c) Money Received Against Share Warrants	-	2,311.04
	Sub Total - Shareholders Funds	26,089.66	22,696.97
2	Non-Current Liabilities		
	(a) Long Term Borrowings	403.24	1,194.55
	(b) Other Long term Liabilities	232.74	191.74
	(c) Deferred Tax Liabilities (Net)	-	-
	(d) Long Term Provisions	69.89	53.03
	Sub Total - Non Current liabilities	705.87	1,439.32
3	Current Liabilities		
	(a) Short Term Borrowings	1,777.35	2,512.38
	(b) Trade Payables	489.47	351.85
	(c) Other Current Liabilities	1,210.83	883.76
	(d) Short Term Provisions	59.99	351.33
	Sub Total - Current Liabilities	3,537.64	4,099.32
	TOTAL - EQUITY AND LIABILITIES	30,333.17	28,235.61
B	ASSETS		
1	Non-Current Assets		
	(a) Fixed Assets		
	(i) Tangible Assets	7,306.36	7,754.68
	(ii) Intangible Assets	2,972.30	3,205.69
	(iii) work in progress	19.07	0.99
	(b) Non-Current Investments	0.83	0.83
	(c) Deferred Tax Asset (Net)	92.08	9.67
	(d) Long Term Loans & Advances	4,784.62	3,881.78
	Sub Total - Non-Current Assets	15,175.26	14,853.64
2	Current Assets		
	(a) Inventories	5,775.85	3,997.67
	(b) Trade Receivables	8,766.64	8,401.44
	(c) Cash & Cash Equivalents	75.34	191.83
	(d) Short Term Loans & Advances	540.08	791.03
	(e) Other Current Assets	-	-
	Sub Total - Current Assets	15,157.91	13,381.97
	TOTAL ASSETS	30,333.17	28,235.61



[Handwritten signature]

CAMSON BIO TECHNOLOGIES LIMITED

Notes :

- 1 The above Financial Results were reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at it's meeting held on November 13, 2014.
- 2 The Company has opted to publish only unaudited standalone Financial Results. The unaudited consolidated Financial Results for the quarter ended Sept 30, 2014 of the Company will be available on the website of the Company, BSE Limited and BgSE.
- 3 The nature of the company's business being related to agriculture and the composition of income varying due to the underlying environmental and market conditions, the results of the company quarter on quarter can vary significantly and are therefore not comparable.
- 4 The Company has revised depreciation rates on fixed assets effective April 1, 2014 in accordance with requirement of schedule II of Companies Act, 2013 ("the Act"). The remaining useful life has been revised by adopting standard useful life as per the Companies Act, 2013. Consequent upon such change the depreciation amounting to Rs.90.84 lakhs (net of deferred tax of Rs. 8.91 lakhs) has been adjusted against reserves in respect of assets which have already completed their useful lives before April 2014 and for other assets depreciation has been charged based on their remaining useful life. Had the company continued with the previously assessed useful lives, the charge for depreciation would have been lower by Rs. 158 lakhs for the period ended 30th September 2014.
- 5 The dividend proposed for the period 2013-14 was not approved by the share holder's, hence the provision towards dividend and dividend distribution tax has been reversed during the current quarter.
- 6 During the period the company has allotted equity shares on conversion of warrants - 31,00,000 shares of Rs. 10/- each issued at premium of Rs.60 per share and 16,74,327 shares of Rs. 10/- each at a premium of Rs.163.34 per share as per terms of the warrants issued
- 7 Other expenses includes Rs.7.51 crores given as special discount to certain customers against sales made in earlier years.
- 8 The Company operates in two segments i.e. Seeds and Agribiotech products.
- 9 Figures for the previous periods/years have been regrouped/rearranged wherever necessary.

Date : 13.11.2014
Place: Bangalore

For and on behalf of the Board of Directors



DHIRENDRA KUMAR
Managing Director



The Board of Directors
Camson Bio Technologies Limited
Survey No. 132,
Madagondanahalli,
Nelamangala Road,
Doddaballapur,
Bangalore 561 023.

Dear Sirs,

LIMITED REVIEW REPORT

1. We have reviewed the accompanying statement of unaudited financial results of **Camson Bio Technologies Limited** for the quarter and half year ended September 30, 2014, (the Statement) except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' and encumbrances thereon, which have been traced from disclosures made by the management and have not been audited by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free from material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Pune

T + 91 020 60601005/6/7/8/9
+ 91 020 25666932/32926341
E bkkpune@bkkhareco.com
Hotel Swaroop, 4th Floor,
Lane No.10, Prabhat Road,
Erandwane, Pune - 411 004, India

Bengaluru

T + 91 80 41105357
E bkkbengaluru@bkkhareco.com
101, Money Chambers,
1st Floor, # 6 K. H. Road,
Shanthinagar,
Bengaluru - 560027, India

New Delhi

T + 91 011 4182 8360
E bkkdelhi@bkkhareco.com
107, Siddharth Chambers,
Near IIT Gate,
Kalu Sarai, Hauz Khas,
New Delhi - 110 016. India.

3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with the Accounting Standards notified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of
B. K. Khare & Co.
Chartered Accountants
Firm Registration No: 105102W



Padmini Khare Kaicker
Partner
Membership No. 44784

Bangalore
Date: 13 November 2014

CAMSON BIO TECHNOLOGIES LIMITED
STATEMENT OF UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPT 2014

PART I

Sl. No.	Particulars	Consolidated						Previous Year Ended 31st Mar 2014 (Audited)
		Quarter Ended		Half Year Ended		30th Sept 2013 (Unaudited)	30th Sept 2014 (Unaudited)	
		30th Sept 2014 (Unaudited)	30th June 2014 (Unaudited)	30th Sept 2013 (Unaudited)	30th Sept 2014 (Unaudited)			
1	Income from Operations							
	(a) Net sales / Income from Operations (Net of Excise duty)	4,709.64	4,624.44	5,946.36	9,334.08	9,719.52	19,089.16	
	(b) Other Operating Income	-	-	-	-	-	-	
	Total Income from Operations (net)	4,709.64	4,624.44	5,946.36	9,334.08	9,719.52	19,089.16	
2	Expenses							
	(a) Cost of Materials consumed	1,721.97	691.98	490.00	2,413.95	781.21	2,104.56	
	(b) Purchase of stock-in-trade	2,414.60	1,034.59	3,886.32	3,449.19	5,275.83	9,320.98	
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2,428.94)	896.14	(379.88)	(1,532.80)	73.29	(332.76)	
	(d) Employee benefits expense	349.40	310.27	227.51	659.67	409.30	935.16	
	(e) Depreciation and amortisation expense	335.99	334.18	125.58	670.17	249.03	511.37	
	(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)							
	i Geo- Climatic Trials	138.73	190.50	85.27	329.23	137.04	410.59	
	ii Selling and Promotion Expenses	819.08	143.29	746.86	962.37	1,068.26	1,933.25	
	iii Other Expenses	1,223.74	637.09	601.69	1,860.83	901.57	2,246.44	
	Total Expenses	4,574.57	4,238.04	5,783.35	8,812.61	8,895.52	17,129.59	
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	135.07	386.40	163.01	521.47	824.00	1,959.57	
4	Other Income	15.10	1.55	31.19	16.65	43.90	53.32	
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)	150.17	387.95	194.20	538.12	867.90	2,012.89	
6	Finance Cost	83.96	115.23	85.29	199.19	175.22	387.59	
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	66.21	272.72	108.91	338.93	692.68	1,625.30	
8	Exceptional Items	-	-	-	-	356.30	356.30	
9	Profit / (Loss) from ordinary activities before tax (7 ± 8)	66.21	272.72	108.91	338.93	336.38	1,269.00	
10	Tax Expense	44.18	(123.41)	56.45	(79.23)	66.45	(47.90)	
11	Net Profit / (Loss) from Ordinary Activities after tax (9 ± 10)	22.03	396.13	52.46	418.16	269.93	1,316.90	
12	Extraordinary Items (net of tax expenses)	-	-	-	-	-	-	
13	Net Profit / (Loss) for the period (11 ± 12)	22.03	396.13	52.46	418.16	269.93	1,316.90	
14	Share of Profit / (loss of associates)	-	-	-	-	-	-	
15	Minority Interest	(1.32)	(4.54)	7.05	(5.86)	0.37	(0.88)	
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 ± 14 ± 15)	23.35	400.67	45.41	424.02	269.56	1,317.78	
17	Paid up Equity Share Capital (Face value of the Share is Rs. 10/-)	2,999.98	2,832.55	2,522.55	2,999.98	2,522.55	2,522.55	
18	Reserves excluding Revaluation Reserve as per Balance Sheet of the Previous Accounting Year						17,904.22	
19.i	Earning per share (before extraordinary items) (of Rs.10 /- each) (not annualised): Rs							
	(a) Basic	0.08	1.57	0.19	1.81	1.10	5.61	
	(b) diluted	0.08	1.27	0.16	1.54	0.98	4.79	
19.ii	Earning per share (after extraordinary items) (of Rs.10 /- each) (not annualised): Rs							
	(a) Basic	0.08	1.57	0.19	1.81	1.10	5.61	
	(b) diluted	0.08	1.27	0.16	1.54	0.98	4.79	



/s/

CAMSON BIO TECHNOLOGIES LIMITED

PART II SELECT INFORMATION FOR THE QUARTER AND HALF YEAR ENDED AS ON 30TH SEPT 2014

Sl. No.	Particulars	Consolidated							Previous Year Ended 31st Mar 2014 (Audited)
		Quarter Ended			Half Year Ended		30th Sept 2013 (Unaudited)	30th Sept 2014 (Unaudited)	
		30th Sept 2014 (Unaudited)	30th June 2014 (Unaudited)	30th Sept 2013 (Unaudited)	30th Sept 2014 (Unaudited)	30th Sept 2014 (Unaudited)			
A	PARTICULARS OF SHAREHOLDING								
1	Public Shareholding	2,26,61,240	2,09,86,913	1,74,86,913	1,24,08,616	1,74,86,913	1,74,86,913	1,85,86,913	
	- Number of Shares *	75.54%	74.09%	78.33%	68.44%	78.33%	78.33%	73.68%	
2	Promoters and Promoter group shareholding								
a)	Pledged/Encumbered - Number of Shares	0%	0%	0%	0%	0%	0%	0%	
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0%	0%	0%	0%	0%	0%	0%	
	Percentage of shares (as a % of the total share capital of the company)	0%	0%	0%	0%	0%	0%	0%	
b)	Non-encumbered								
	Number of shares	73,38,600	73,38,600	48,38,600	57,21,384	48,38,600	48,38,600	66,38,600	
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%	100%	
	Percentage of Shares (as a % of the total Share Capital of the Company)	24.46%	25.91%	21.67%	31.56%	21.67%	21.67%	26.32%	

B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	Nil
	Disposed of during the quarter	Nil
	Remaining unresolved at the end of the quarter	Nil



(Handwritten signature)

CAMSON BIO TECHNOLOGIES LIMITED
REPORT OF SEGMENT-WISE CONSOLIDATED REVENUE, RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE 41 OF THE LISTING AGREEMENT FOR QUARTER AND HALF YEAR ENDED AS ON 30TH SEPT 2014

Sl. No.	Particulars	Consolidated						Previous Year Ended 31st Mar 2014 (Audited)
		Quarter Ended		Half Year Ended		30th Sept 2013 (Unaudited)	30th Sept 2013 (Unaudited)	
		30th Sept 2014 (Unaudited)	30th June 2014 (Unaudited)	30th Sept 2014 (Unaudited)	30th Sept 2014 (Unaudited)			
1	Segment Revenue	2,424.66	3,598.73	4,567.42	6,023.39	7,573.71	14,758.88	
	a) Seeds	2,284.99	1,025.70	1,378.94	3,310.69	2,145.81	4,383.60	
	b) Agribiotech Products	4,709.65	4,624.43	5,946.36	9,334.08	9,719.52	19,142.48	
	c) Others	-	-	-	-	-	-	
	Total	4,709.65	4,624.43	5,946.36	9,334.08	9,719.52	19,142.48	
	Less: Intersegment Revenue	-	-	-	-	-	-	
	Net Sales/ Income from Operation	4,709.65	4,624.43	5,946.36	9,334.08	9,719.52	19,142.48	
2	Segment Results	(77.00)	486.27	145.56	409.27	433.30	2,086.81	
	a) Seeds	479.04	92.86	114.15	571.90	303.61	432.42	
	b) Agribiotech Products	402.04	579.13	259.71	981.18	736.91	2,519.23	
	Total	250.56	1,86.64	72.54	437.20	225.68	861.76	
	Less: (i) Other Income - Non operating and unallocated expenses (net)	83.96	115.23	85.29	199.19	175.22	387.59	
	(ii) Finance Cost	67.52	277.26	101.88	344.78	336.01	1,269.88	
3	Total Profit before Tax	13,079.65	13,063.54	12,401.53	13,079.65	12,401.53	15,907.38	
	Capital Employed	8,863.12	9,093.47	7,069.76	8,863.12	7,069.76	5,435.09	
	(Segment Assets-Segment Liabilities)	4,184.57	1,396.28	1,258.13	4,184.57	1,258.13	1,395.34	
	a) Seeds	26,127.34	23,553.29	20,729.42	26,127.34	20,729.42	22,737.81	
	b) Agri Biotech products	-	-	-	-	-	-	
	c) Others	-	-	-	-	-	-	
	TOTAL	26,127.34	23,553.29	20,729.42	26,127.34	20,729.42	22,737.81	



CAMSON BIO TECHNOLOGIES LIMITED

STATEMENT OF ASSETS AND LIABILITIES UNDER CLAUSE 41(V) OF THE LISTING AGREEMENT
PARTICULARS

Sl.		As at 30-Sept-14 (Unaudited)	Consolidation As at 31-Mar-14 (Audited)
A	EQUITY AND LIABILITIES		
1	Shareholders' Funds		
	(a) Share Capital	2,999.98	2,522.55
	(b) Reserves and Surplus	23,127.36	17,904.22
	(c) Money Received Against Share Warrants	-	2,311.04
	Sub Total - Shareholders Funds	26,127.34	22,737.81
2	Minority Interest	20.64	26.49
3	Non-Current Liabilities		
	(a) Long Term Borrowings	403.24	1,194.55
	(b) Other Long term Liabilities	232.74	191.74
	(c) Deferred Tax Liabilities (Net)	-	-
	(d) Long Term Provisions	71.84	54.15
	Sub Total - Non Current Liabilities	707.82	1,440.44
4	Current Liabilities		
	(a) Short Term Borrowings	2,231.28	2,512.38
	(b) Trade Payables	1,151.47	1,102.24
	(c) Other Current Liabilities	1,230.32	898.44
	(d) Short Term Provisions	109.67	410.92
	Sub Total - Current Liabilities	4,722.74	4,923.98
	TOTAL - EQUITY AND LIABILITIES	31,578.54	29,128.72
B	ASSETS		
1	Non-Current Assets		
	(a) Fixed Assets		
	(i) Tangible Assets	7,307.30	7,755.76
	(ii) Intangible Assets	2,972.30	3,205.69
	(iii) work in progress	19.07	0.99
	(b) Good will on consolidation	0.25	0.25
	(c) Non-Current Investments	0.18	0.18
	(d) Deferred tax Assets (Net)	99.13	10.99
	(e) Long Term Loans & Advances	4,794.93	4,081.35
	Sub Total - Non-Current Assets	15,193.16	15,055.21
2	Current Assets		
	(a) Inventories	5,805.29	4,041.49
	(b) Trade Receivables	9,862.41	9,354.58
	(c) Cash & Cash Equivalents	154.99	195.62
	(d) Short Term Loans & Advances	562.69	481.82
	(e) Other Current Assets	-	-
	Sub Total - Current Assets	16,385.38	14,073.51
	TOTAL ASSETS	31,578.54	29,128.72



[Handwritten Signature]

CAMSON BIO TECHNOLOGIES LIMITED

Notes :

- 1 The above Financial Results were reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at its meeting held on November 13, 2014.
- 2 The Company has opted to publish only unaudited standalone Financial Results. The unaudited consolidated Financial Results for the quarter ended Sept 30, 2014 of the Company will be available on the website of the Company, BSE Limited and BgSE.
- 3 The nature of the company's business being related to agriculture and the composition of income varying due to the underlying environmental and market conditions, the results of the company quarter on quarter can vary significantly and are therefore not comparable.
- 4 The Company has revised depreciation rates on fixed assets effective April 1, 2014 in accordance with requirement of schedule II of Companies Act 2013 ("the Act"). The remaining useful life has been revised by adopting standard useful life as per the Companies Act, 2013. Consequent upon such change the depreciation amounting to Rs.90.84 lakhs (net of deferred tax of Rs. 8.91 lakhs) has been adjusted against reserves in respect of assets which have already completed their useful lives before April 2014 and for other assets depreciation has been charged based on their remaining useful life. Had the company continued with the previously assessed useful lives, the charge for depreciation would have been lower by Rs. 158 lakhs for the period ended 30th September 2014.
- 5 The dividend proposed for the period 2013-14 was not approved by the share holders, hence the provision towards dividend and dividend distribution tax has been reversed during the current quarter.
- 6 During the period the company has allotted equity shares on conversion of warrants - 31,00,000 shares of Rs. 10/- each issued at premium of Rs.60 per share and 16,74,327 shares of Rs. 10/- each at a premium of Rs.163.34 per share as per terms of the warrants issued
- 7 Other expenses includes Rs.7.51 crores given as special discount to certain customers against sales made in earlier years.
- 8 The Company operates in two segments i.e. Seeds and Agribiotech products.
- 9 Figures for the previous periods/years have been regrouped/rearranged wherever necessary.

Date : 13.11.2014
Place: Bangalore

For and on behalf of the Board of Directors



DHIRENDRA KUMAR
Managing Director



The Board of Directors
Camson Bio Technologies Limited
Survey No. 132,
Madagondanahalli,
Nelamangala Road,
Doddaballapur,
Bangalore 561 023.

Dear Sirs,

LIMITED REVIEW REPORT

1. We have reviewed the accompanying statement of consolidated unaudited financial results of Camson Bio Technologies Limited for the quarter and half year ended September 30, 2014, (the Statement) except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' and encumbrances thereon, which have been traced from the disclosures made by the Management and have not been audited by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed By The Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free from material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. We did not review the interim financial results of the subsidiary included in the consolidated unaudited financial results, whose interim financial statements reflect total assets of Rs. 171,716,452/- as at 30 September 2014 and revenues of Rs. 162,585,972/- for the period then ended respectively. These interim financial results have been reviewed by other auditor whose report has been furnished to us. Our conclusion on the consolidated unaudited financial results, in so far as it relates to such subsidiary is based solely on the report of the other auditor.

Pune

T + 91 020 60601005/6/7/8/9
+ 91 020 25666932/32926341
E bkkpune@bkkhareco.com
Hotel Swaroop, 4th Floor,
Lane No.10, Prabhat Road,
Erandwane, Pune - 411 004, India

Bengaluru

T + 91 80 41105357
E bkkbengaluru@bkkhareco.com
101, Money Chambers,
1st Floor, # 6 K. H. Road,
Shanthinagar,
Bengaluru - 560027, India

New Delhi

T + 91 011 4182 8360
E bkkdelhi@bkkhareco.com
107, Siddharth Chambers,
Near IIT Gate,
Kalu Sarai, Hauz Khas,
New Delhi - 110 016. India.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited consolidated financial results prepared in accordance with the Accounting Standards notified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of
B. K. Khare & Co.
Chartered Accountants
Firm Registration No. 105102W



Padmini Khare Kaicker
Partner
Membership No. 44784

Bangalore
Date: 13 November 2014

Camson Biotechnologies: Q2 & half year ended 30 September 2014 Results Release

**Biocide business surges during Q2. Sales up 60%, profits up more than 3 times y-o-y.
Strong results despite adverse climatic conditions.**

Financial Performance Highlights:

Highlights of Q2 2014-15

Rs. Lakhs

	Q2 -2014-15	Q2-2013-14	% Change
Sales	4156.96	3191.99	30
EBDITA	459.35	268.01	71

Biocides Segment
Highlights

Rs.Lakhs

	Q2 -2014-15	Q2 -2013-14	% Change
Sales	2208.4	1379.36	60
Segment Revenue	365.01	114.2	220


Q2 FY 14-15 results compared with Q2 FY 13-14 results:

Revenues increase by 30 % to Rs.41.6 crore from Rs. 31.9 crore

EBDITA stands at Rs.4.6 crore versus Rs. 2.7 crore, a growth of 71%

Mumbai, November 13th, 2014: Camson Biotechnologies Limited declared a total income of Rs. 41.6 crore for the Q2 of FY 14-15 on a standalone basis. This is a strong growth of 30% over corresponding period's total income of Rs.31.9 crore. EBDITA jumped 71% to 4.6 crore compared to Rs.2.7 crore a year ago.

During the quarter, the biocides business of the company grew by a strong 60% to Rs.22 crore compared to Rs.13.8 crore in the corresponding quarter a year ago. The strong growth in the biocides business is testimony to the faith that the farmers have shown in Camson's technologically advanced products. The jump in sales comes on the back of huge increase in volumes aided by new products launched.



The company has expanded its dealer network across new markets and is also aggressively exploring opportunities in the institutional space. These strategic initiatives will fuel growth in the coming months.


Commenting on the results, **Santosh Nair, CEO, Camson Biotechnologies Ltd.**, said, "As envisaged by us, Camson's biocides business has done exceedingly well and become the larger of the two verticals that we have. Farmers have increasingly taken to these technologically advanced products that help to protect their fields and provide safe and healthy produce for consumers. Our investments in R&D have made us a formidable name in the bio agri input industry. This is just the beginning of the exciting times that we look forward to."

R&D & Projects

Camson Biotechnologies has built up its position on innovation-led R&D, for developing better quality agro-products for crop protection and higher yield hybrid seeds. It remains focussed on this approach. The new building constructed at our mother plant in Dodballapur houses a new state-of-the art laboratory & research centre. While, the production facility at Dodaballapur services the markets of southern and western India, the company's manufacturing & production facilities at it's Nangal plant in Himachal Pradesh cater to the increasing demand from its strategic and key markets of Northern and Eastern India.

+++

About Camson Biotech- Established in 1993, Camson Biotechnologies combines the latest knowledge in breeding, molecular genetics and metagenomics in agriculture with the latest practices in environmental safety and protection, to market a wide range of products spanning hybrid seeds, bio-fertilizers and biocides. These are non-poisonous, eco-friendly and residue-free. Headquartered in Bangalore, Camson Biotechnologies employs the best talent in the industry to bring innovative biotechnology products to the farmers. Partnering with farming communities, government agencies and corporate houses in India, Camson Biotechnologies aims at empowering farming communities by focussing its R&D to their needs.





CAMSON

For more information:

Sunil Ramakirshnan

Rigveda consultancy & Services

Mobile: - 09870110525

Corporate Headquarters:

Camson Biotechnologies Ltd

C-7, 7th Floor, Corporate Block,

Golden Enclave, Airport Road,

Bangalore 560 017.

Tel: 080 40768900

Email: info@camsonbiotechnologies.com

CIN : L85110KA1993PLCO14944

R&D Center:

Camson R&D

Dodaballapur, 561203

Tel: 0091 081 19329874

Fax: 0091 080 2535 2232

Email: research@camsonbiotechnologies.com

Website: www.camsonbiotechnologies.com/research



13/11/14